期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 24, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/ijms24010446
关键词
heart failure with reduced ejection fraction; myosin activators; danicamtiv; positive inotropy; strain; diastolic dysfunction
Recent cardiotropic drug developments have focused on cardiac myofilaments, and danicamtiv, as the second direct myosin activator, has shown promising results in the treatment of heart failure with reduced ejection fraction. In vitro and in vivo studies have demonstrated that danicamtiv improves systolic function but may also limit diastolic performance at higher concentrations.
Recent cardiotropic drug developments have focused on cardiac myofilaments. Danicamtiv, the second direct myosin activator, has achieved encouraging results in preclinical and clinical studies, thus implicating its potential applicability in the treatment of heart failure with reduced ejection fraction (HFrEF). Here, we analyzed the inotropic effects of danicamtiv in detail. To this end, changes in sarcomere length and intracellular Ca2+ levels were monitored in parallel, in enzymatically isolated canine cardiomyocytes, and detailed echocardiographic examinations were performed in anesthetized rats in the absence or presence of danicamtiv. The systolic and diastolic sarcomere lengths decreased; contraction and relaxation kinetics slowed down with increasing danicamtiv concentrations without changes in intracellular Ca2+ transients in vitro. Danicamtiv evoked remarkable increases in left ventricular ejection fraction and fractional shortening, also reflected by changes in systolic strain. Nevertheless, the systolic ejection time was significantly prolonged, the ratio of diastolic to systolic duration was reduced, and signs of diastolic dysfunction were also observed upon danicamtiv treatment in vivo. Taken together, danicamtiv improves cardiac systolic function, but it can also limit diastolic performance, especially at high drug concentrations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据